CYBERVEIN FOUNDATION LTD.
UEN: 201804838Z
CYBERVEIN FOUNDATION LTD.(201804838Z) is a Singapore business with registered business address at 6 EU TONG SEN STREET, 12-17, THE CENTRAL, Singapore 59817. They specialise in the area of DEVELOPMENT OF OTHER SOFTWARE AND PROGRAMMING ACTIVITIES N.E.C..
| Company Name | CYBERVEIN FOUNDATION LTD. |
| Unique Entity Number | 201804838Z |
| Entity Type | Local Company |
| Entity Status | Live Company |
| Incorporate Day | 07 February 2018 |
| Address |
6 EU TONG SEN STREET #12-17 THE CENTRAL Singapore 59817 |
| Products / Services | DEVELOPMENT OF OTHER SOFTWARE AND PROGRAMMING ACTIVITIES N.E.C. |
| Number of Officers | 3 |
Breaking! Business News
Building the optimised data centreSchneider Electric - Around the world, cloud and IT providers are scaling their capabilities and acc...
Read More
The Beethoven Experience in Shanghai, China[19 September 2020] Classical music composer Ludwig van Beethoven was born 17 December 1770, and wen...
Read More
Imperial Capital Expands Emerging Markets Sales with the Hiring of Erik HammesImperial Capital Expands Emerging Markets Sales with the Hiring of Erik Hammes GlobeNew...
Read More
Radient Conducts Strategic Review of Operations and Announces Management ChangesRadient Conducts Strategic Review of Operations and Announces Management Changes GlobeN...
Read More
PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trialsPRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment ...
Read More
Secureworks Named a Leader in the IDC MarketScape: Worldwide Managed Security Services (MSS) 2020 Vendor AssessmentSecureworks Named a Leader in the IDC MarketScape: Worldwide Managed Security Services (MSS) 2020 Ve...
Read More
Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue SarcomaJunshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatm...
Read More
Fresche Announces Expansion to its Automated Solutions that Accelerate IBM i (AS/400) Application Transformation to Modern LanguagesFresche Announces Expansion to its Automated Solutions that Accelerate IBM i (AS/400) Application Tr...
Read More